NIBSC - Key Persons
Job Titles:
- Member of the NIBSC Management Team
- Head of Standards Processing Division
Job Titles:
- Head of Business Development
- Member of the NIBSC Management Team
Job Titles:
- Senior Scientist, Molecular Immunology Section
Bernard joined NIBSC in 2000 after working in the plasma products industry for eight years and working as a biomedical scientist in pathology. During his time at NIBSC he has worked on over 20 new and replacement standards projects.
He's currently study director for albumin solutions and responsible for the Independent Control Testing of over 300 batches each year. Over the years he has supported batch release testing of albumin and immunoglobulin products by developing new test methods to improve product safety. For example, one method has now been adopted as a Ph Eur test method to control the levels of anti- A, anti-B and anti-D in immunoglobulin products.
He is jointly responsible for a portfolio of over 40 standards covering immunoglobulins/antibody quantitation, serological/blood grouping, haemoglobin, haematinics and auto-immunity.
He is also product supervisor for our CE marked anti-D and anti-c products.
His main research interests are antibody characterisation and the development of polyclonal and monoclonal antibodies with diagnostic and/or therapeutic potential.
Job Titles:
- Senior Scientist
- in 1998 As a Scientist
Clare joined NIBSC in 1998 as a scientist responsible for screening plasma pools for the presence of HIV, following a 2-year graduate post at Hammersmith Hospital working on an HIV drug response clinical trial.
She now has over 16 years of experience in the field of development of international standards and working reagents.
Her main interests are the development of international standards for use in clinical diagnosis and the improvement of current standards to adapt to new technologies.
Dr Alexandra Shaw leads the Group A Streptococcus research area within the Streptococcal and Hib group in the Division of Bacteriology. She has a longstanding interest in vaccine development in Gram positive bacteria, especially investigating novel vaccination formulations and delivery. Her projects at the NIBSC investigate multicomponent protein vaccines and innovative methods towards producing effective glycoconjugate vaccines against Group A Streptococcus in collaboration with Professor Brendan Wren (LSHTM) and Dr Helge Dorfmueller (Dundee University). The team are also investigating the mucosal immune response to Group A Streptococcus infection and vaccination, in collaboration with Dr Thushan de Silva (Sheffield University).
Prior to her fellowship at the NIBSC, Allie obtained a BSc (Hons) in Biochemistry from Imperial College London and completed a PhD in Molecular Microbiology in the Division of Cell and Molecular Biology at Imperial College London investigating cell wall proteins of C. difficile in collaboration with Novartis Vaccines (now GSK) in Siena, Italy. During a postdoctoral position at the London School of Hygiene and Tropical Medicine (LSHTM) she continued her work investigating sortase and cell wall proteins of C. difficile, as well as coordinating a multicentre study to sequence and characterise strains from Clade 3 of C. difficile (RT023).
Following completion of his PhD at Imperial College, London, Dr Andrew Macadam moved to NIBSC as a postdoc in 1987 working on the molecular basis of attenuation of poliovaccines. He joined the staff permanently in the 1990s and is currently a Principal Scientist in the Division of Virology where he runs a research group with interests in new approaches to polio vaccine design.
Job Titles:
- Head of Flow Cytometry Standardisation
Dr Anna Nowocin is the Head of Flow Cytometry Standardisation at NIBSC. Her main responsibilities include development of flow cytometry reference materials and controls, overseeing the work of the flow cytometry facility and the development of predictive cell-based assays that can aid assessment of safety and potency of therapeutic products. She is an active member of several internal and external committees and advisory/working groups.
Job Titles:
- Section Leader, Haemostasis
From a background in novel drug delivery and analysis, Dr Anthony Hubbard joined NIBSC in 1982 to undertake testing, standardisation and research activities related to the diagnosis and treatment of disorders of blood coagulation.
He is currently leader of the Haemostasis Section in the Biotherapeutics Group. The Section is responsible for the Independent Control Testing of plasma-derived therapeutics and the development of over 40 WHO International Standards related to the diagnosis and therapy of bleeding and thrombotic disorders. These core activities are complemented by research activities, including the evaluation of new therapeutics, and advisory roles on scientific committees.
Job Titles:
- Group Leader, Physico - Chemical Analysis Group
Barbara Bolgiano joined the NIBSC in 1993 to evaluate bacterial proteins and other biologicals, pre- and post-licensure. She is currently the Group Leader of the Physico-chemical Analysis Group in the Division of Bacteriology and her laboratory performs quality evaluation, structural determination and stability testing of vaccine antigens, including saccharide-protein conjugate vaccines used for the prevention of meningitis, whooping cough, and other invasive diseases.
Job Titles:
- in 2015 As a Senior Scientist
Ben joined NIBSC in 2015 as a Senior Scientist in the Endocrinology section. He has over 10 years' experience in the production, engineering, purification and physicochemical analysis of therapeutic peptides and proteins.
Ben studied at the University of Nottingham, then at Imperial College London, where he received a PhD in Structural Molecular Biology in 2012. His PhD project involved atomic structure determination and carbohydrate-binding studies of a cell-adhesive protein from Toxoplasma gondii using NMR spectroscopy. He then worked as a postdoctoral researcher at University College London, on the development of chemically-modified (e.g. PEGylated, glycosylated, cyclised) therapeutic proteins/peptides.
Ben is currently working on the development of reference materials (including WHO International Standards) for proteins hormones and endocrine products. He also provides expertise in the physicochemical analysis of wider biotherapeutic products, through the development, optimisation and application of (U)HPLC-MS techniques, with a strong focus on N-glycan analysis.
Dr Bhagwati Khatri is a senior scientist leading Tuberculosis (TB) research at NIBSC. Bhagwati's research interest lies in understanding the immune response in protection against Mycobacteria tuberculosis, the causative agent of TB. In collaboration with many research and academic institutes, she is evaluating BCG efficacy in a co-infection (TB and malaria) and TB meningitis mouse model for deciphering comprehensive immune response parameters. Multi-Drug Resistant TB is one of the major challenges and she is interested in establishing proof-of-concept in using engineered macrophages as an immunotherapy for TB.
The NIBSC TB research group has an established TB aerosol mouse model and Bhagwati is open for collaborations across the TB field.
Bhagwati has extensive knowledge and experience in the field of TB and prior to moving to NIBSC, she was working in the field of vaccine development against Bovine TB in cattle at Animal and Plant Health Agency (APHA), UK. Her PhD was in Organic Chemistry from India and started working at the APHA, UK in the diagnostic and research divisions.
Job Titles:
- Principal Scientist
- Administrator Role of the Institute
With an academic background focussed on the production, purification and characterisation of monoclonal antibodies, Carl Dolman began working with NIBSC in 1996 and has since become the Study Director of the Therapeutic Immunoglobulins and Allergens area. This is now part of the larger Molecular Immunology Section within the Biotherapeutics Group.
His team is responsible for the control testing of several hundred batches of therapeutic immunoglobulin per year, as well as a few allergen products that include grass pollen, bee and wasp venom. His group has also participated in many European Directorate for the European Directorate for the Quality of Medicines and Healthcare (EDQM) run biological standardisation programs (BSP: 039, 044, 068, 071, 099, 108, 122, 160) such as the establishment of Human Immunoglobulin for Electrophoresis BRP Batch 4 (BSP160).
Carl has been an active participant at annual OMCL meetings since 1999 and became an elected member of the Advisory Group to the General OMCL network (AdG-GEON) in 2011 for four years. He is responsible for extraction of the control testing data for the NIBSC annual OMCL reports for both blood products and vaccines.
Present research interests include; HPLC analysis of biosimilars, purification of virus particles, affinity purification and analysis of HIV envelope proteins; study of aggregate and dimer levels in therapeutic immunoglobulins, purification of monoclonal antibodies for use as international standards. He is currently working on establishing an HPLC aggregate standard for use in the immunoglobulins control testing assay ‘Distribution of molecular size' and has taken part in recent EDQM organised Proficiency Testing Schemes (PTS) for this assay (PTS202).
Another major role for Carl is the administrator role of the Institute's batch release database "CT-LIMS" that handles sample information from receipt at NIBSC through to testing, results entry and authorisation including the automatic dispatch of a National Control Authority release certificate to the manufacturer.
Job Titles:
- Senior Scientist, Haemostasis Section
Dr Coxon studied undergraduate biochemistry at the University of Bath. She then obtained a PhD from the University of Reading in cardiovascular science and myocardial regeneration, moving then to the University of Oxford to characterise a novel platelet receptor, G6b in the laboratory of Dr Duncan Campbell. During this time she lead collaborative projects pertaining to pharmacology and drug discovery, as well specialising in biochemical and biophysical approaches to studying protein-protein interactions. Subsequent positions at the Weatherall Institute of Molecular Medicine (Oxford), the Dept. Physiology, Pharmacology and Neuroscience in Bristol, and the Target Discovery Institute (Structural Genomics Consortium, Oxford) further developed her expertise in biochemistry, biophysical assays, and drug discovery.
Dr Coxon has long been interested in cardiovascular disease, specifically aspects of thrombosis and haemostasis, and she is keen to scientifically contribute to improving the quality and application of therapeutics used to treat bleeding disorders. Working with Dr Sanj Raut, as a Post-Doctoral Fellow, she is currently engaged in the development and implementation of reference materials aimed at reducing the unacceptably high variability in haemophilia A inhibitor testing.
Job Titles:
- Principal Scientist
- Chairman of the Meningitis Now Charity 's Scientific
- Senior Scientist in the Meningococcal and Pneumococcal Laboratory
Dr Caroline Vipond is a Senior Scientist in the Meningococcal and Pneumococcal laboratory at NIBSC and is responsible for the release of meningococcal polysaccharide and protein-based vaccines.
Her primary research interests are on meningococcal protein-based vaccines, characterization of complex products with a focus on developing assays to effectively measure vaccine potency and safety with a view to using non-animal models.
In addition, Caroline oversees the panel of meningococcal reference material, including a panel of typing monoclonal antibodies, ELISA reagents and production of WHO international standards.
Caroline obtained her PhD from Imperial College London in 2010 in the field of outer membrane vesicle and degree in Molecular and Cellular Biology from the University of Bath in 1999.
Caroline is the chair of the Meningitis Now Charity's Scientific and Medical Advisory Panel.
If you are interested in collaborating with Caroline on pneumococcal or meningococcal research projects please contact meningovac@nibsc.org
Job Titles:
- Member of the NIBSC Management Team
- Head of Biotherapeutics
- Head of Biotherapeutics Division
Dr Chris Burns joined NIBSC in 2005, initially as a Principal Scientist and then Head of the Endocrinology section. In 2017, he took over as Head of the Division of Biotherapeutics. He has more than 20 years' research experience obtained initially through doctoral studies and post-doctoral academic research at King's College London and more recently at NIBSC. He has published more than 50 refereed publications and sits on a number of national and international committees and advisory boards relating to medicine safety, international standardisation and the harmonisation of diagnostic tests. He works closely with the World health Organisation, EDQM, the European and US Pharmacopoeias and the International Federation of Clinical Chemistry and Laboratory Medicine.
His research interests are focussed in two major areas. The first underpins the activities of the Division of Biotherapeutics at NIBSC and involves the characterisation of biological medicines such as glycoprotein hormones and monoclonal antibodies using physico-chemical and biological assays, and the development of novel and improved methods for these analyses. The second is a program of work using cellular reprogramming to generate induced pluripotent stem cells for studies into the safety of stem cell therapies. These cells have enormous clinical potential for regenerative medicine applications.However, the successful translation of this potential into effective strategies to treat disease relies on a better understanding of the recipient's immune response to the transplanted cells, and also how these immune responses may be mitigated.
Dr Chris Jones joined NIBSC in 1982 and went on to become Head of the Laboratory for Molecular Structure, prior to his retirement in 2015. He was responsible for developing, implementing and validating sophisticated physico-chemical methods (including NMR, circular dichroism, mass spectrometry, HPLC, peptide and glycan mapping) for the characterisation of complex biological products, with a particular focus on polysaccharide and glyco-conjugate vaccines.
Job Titles:
- Leader, Microbiome Group
- Member of Expert Committees
Dr Chrysi Sergaki is the Microbiome Group Leader at MHRA, under Diagnostics R&D, Science, Research and Innovation. At MHRA she is leading the Microbiome Standardisation Program, with 18 World Health Organization (WHO) endorsed projects to develop International Reference Reagents for the microbiome field as well as research projects investigating the role of the microbiome in health and disease through collaborations with NHS, Kings College University, the Francis Crick Institute, Liverpool University and Warwick University Hospital. Chrysi has led the establishment of the 1 st WHO International DNA Reference Reagents for microbiome analysis, by leading and coordinating a large, international collaborative study. Further to the scientific work, Chrysi has secured funding from BEIS, via the Regulators' Pioneer Fund, to develop microbiome guidelines aiming at facilitating the regulatory process for novel microbiome therapeutics and diagnostics (MHRA to receive nearly £1m BEIS funding to unlock digital, data and scientific regulatory innovation - GOV.UK (www.gov.uk)).
Prior to this, Chrysi has been working at MHRA as scientist since 2019 leading research projects as well as the development of reference reagents for the DNA extraction of microbiome samples and will be evaluated as candidates for the first World Health Organization Whole Cell Reference Reagents for the microbiome. Before joining the MHRA, Chrysi completed her PhD at the University of Warwick, UK, researching microbial interactions in fungi and bacteria and their impact on the host.
Chrysi is a member of expert committees and advisory panels on collaboratives projects, such as the International Human Microbiome Coordination and Support action (IHMCSA) Strategic Steering Committee, the Gut Microbiota for Health Expert panel in the UK, the International Microbiome and Multi'omic Standards Alliance (IMMSA), the Pistoia Alliance and many more. She is very keen on the advancements in the microbiome field and keeping up to date with latest research. If you are interested in microbiome research and its impact, or/and the standardisation of the field, Chrysi would be very interested in hearing from you.
Colin trained in biochemistry at the University of Liverpool, Harvard Medical School and Imperial College, London and has been a scientist with NIBSC since 1989. Here he has worked in the area of haemostasis and particularly fibrinolysis to develop International Standards for the World Health Organisation (WHO). Colin's research interests are centred on enzymology and the regulation of fibrinolysis, recently including the effects of Neutrophil Extracellular Traps (NETs) of DNA and histones incorporated into fibrin clots.
A full list of Colin's publications and recent work can be found on his Researcher ID and ORCID ID pages.
Job Titles:
- Senior Scientist, Haemostasis Section
Since joining the NIBSC in 2002 Craig has worked in the haemostasis and fibrinolysis area of the Biotherapeutics Division. His main responsibilities are developing WHO International Standards for coagulation factors and related enzymes and inhibitors, and performing research that underpins these activities. He is also responsible for the Independent Control Testing of Virus Inactivated (VI) Human Plasma.
With a background in molecular biology and protein biochemistry, Craig uses recombinant protein technologies and molecular techniques to study the enzyme kinetics of, and the interactions between, components of the fibrinolytic and coagulation pathways. His research interests have focused on the structure-function relationship of plasminogen activators used in thrombolytic therapy, and of bacterial virulence factors that hijack the mammalian haemostasis system. These include plasminogen activators, coagulases and associated cell surface receptors.
Job Titles:
- Principal Scientist
- Senior Scientist
Dr Ferguson is a Senior Scientist at NIBSC with research interests including the pathology and disease aetiology of chronic viral infection.
Dianna Wilkinson is a molecular and cellular biologist by training, having earned both a first class honours degree in Biotechnology (1996) and a PhD in Biochemistry (2000) from University College London.
After her PhD, Dianna worked at the University of Connecticut Health Center as a post-doctoral research fellow investigating the cellular biology of Herpes Simplex Virus Type I infection, particularly with respect to the cellular response to DNA damage.
In 2006, she came to NIBSC as a post-doctoral scientist primarily working on the development of WHO international standards for Human papillomavirus (HPV).
In 2009, she was appointed a Principal Scientist in the inactivated viral vaccines (IVV) group in the Division of Virology, working on the standardisation, control and related research of recombinant/inactivated viral vaccines and their viral targets. These include HPV, Hepatitis B Virus (HBV), Rabies and Japanese Encephalitis Virus (JEV).
Dr Donna Bryan joined the NIBSC in 1998. Her research interests are varied having worked on several projects over the years, both in academia and at the NIBSC. Currently, Donna works in the Enterics Group where she manages the research and standardisation projects for the development of reference materials for health care associated infection caused by Clostridioides difficile. Her PhD was obtained in 1998 from Barts and the London school of Medicine and Dentistry, Queen Mary University of London.
Dr Elaine Gray is a Principal Scientist with over 40 years of experience in control and standardisation of haemostasis and thrombosis related biologicals. She is responsible for the production of World Health Organisation (WHO) International Standards and British Standards for coagulation factors II, IX, X, XI; plasma coagulation inhibitors such as Antithrombin and protein C and antithrombotics such as unfractionated and low molecular weight heparin. In addition, she works closely with pharmacopoeias, developing written and physical standards. She is a visiting Professor at the Institute of Pharmaceutical Science, King's College London.
Her current research interests include measurement issues related to modified and novel therapeutics for treatment of haemophilia and non-anticoagulant properties of heparin and heparin related products.
Job Titles:
- Member of the NIBSC Management Team
- Acting Head of Advanced Therapies
- Acting Head of Advanced Therapies / Director of UK Stem Cell Bank
Dr. Elsa Abranches joined the UK Stem Cell Bank team in December 2015 as a Senior Stem Cell Biologist. In January 2019, Dr. Elsa was appointed Group Leader of the Section of Stem Cell Biology and Director of the UK Stem Cell Bank.
Her primary focus is developing and delivering a programme of research and development that assures the quality of both research and clinical grade human pluripotent stem cell lines. Her areas of interest include understanding how gene regulatory networks are assembled, how they function to sustain proper cell fate decisions and how to use this information to achieve efficient, reproducible & cost-effective expansion of human pluripotent stem cell lines.
Dr. Elsa Abranches graduated in 2001 from the Technical University of Lisbon in Chemical Engineering. She was awarded her PhD in the field of Stem Cell Biotechnology where she worked with mouse embryonic stem cells to optimize stem cell growth in bioreactors. She then worked as a post-doctoral researcher initially in the field of neural differentiation and subsequently on self-renewal and pluripotency regulation of embryonic stem cells.
Job Titles:
- Senior Scientist, Physico - Chemical Analysis Group
Frank joined the NIBSC in 2008, he is a Deputy Group Leader of the Physico-chemical Analysis group in the Division of Bacteriology. Frank is responsible for quality control testing of Hib, Meningococcal and typhoid polysaccharide and conjugate vaccines, and has responsibility in leading and overseeing WHO polysaccharide International Standards development. His research is focused in the area of carbohydrate analysis, structural analysis of polysaccharide-protein conjugates and their stability.
Dr Fatme Mawas joined NIBSC in 1997 after completing an MSc in Medical Microbiology (1986) at the London School of Hygiene & Tropical Medicine (LSHTM) and a PhD in Immunology (1995) at King's College London. She is currently a group leader for the Haemophilus and streptococcal laboratory in the Division of Bacteriology. She has over 30 years' experience in biomedical research with 24 years' experience at NIBSC on quality control testing of conjugate vaccines and assays development.
Her group has been responsible for the preparation and evaluation of various WHO and non-WHO reference standards for use in the development and standardisation of various physico-chemical and immunological assays. This includes polysaccharide and human serum standards for Haemophilus influenzae b (Hib) in addition to various reference standards and reagents for Streptococcus agalactiae or Group B Streptococcus (GBS), as part of the GBS consortium project funded by the BMGF.
Hannah Chan has worked in the Meningococcal Vaccines group at NIBSC since 2002. Her main research interests lie in the development and pre-clinical testing of novel vaccines and adjuvants, particularly those based on the meningococcal antigens PorA, FetA and other outer membrane proteins. She has worked on the development of a multiplex assay to measure serological responses to different antigenic variants for PorA and FetA.
Hannah works alongside Caroline Vipond and Rory Care, managing the Meningococcal / Pneumococcal Vaccines group and oversees the majority of the batch release of meningococcal conjugate vaccines.
In addition, Hannah leads projects for the development and maintenance of meningococcal reference materials.
Hannah obtained her PhD from the University of Birmingham in 2002 and a degree in Applied Biology from Imperial College in 1998.
Job Titles:
- Senior Scientist, Haemostasis Section
Dr Jason Long is a Principal Scientist in the Influenza Resource Centre (IRC) in the Division of Virology at NIBSC. The IRC is a WHO Essential Regulatory Laboratory (ERL) in WHO's Global Influenza Surveillance and Response System (GISRS). Together with Dr Othmar Engelhardt, Jason leads a team of scientists who fulfil the IRC's ERL critical functions, connecting surveillance and risk assessment activities with influenza vaccine response, particularly in relation to the development, standardization and regulation of influenza vaccines.
Jason received a doctorate degree from Imperial College London (ICL), joint with the Animal and Plant Health Agency (APHA), under supervision from Professor Wendy Barclay (ICL) and Dr Jill Banks (APHA), which examined virulence mechanisms of highly pathogenic avian influenza H5N1 viruses. Postdoctoral research at ICL included the discovery of an essential host factor, ANP32A, and its role in the host restriction of the influenza virus polymerase.
Jason's research interests focus on the exploitation of Influenza virus' reliance on host cellular factors as a means to identify novel interventions and tools. Current research includes the investigation of novel methods to generate candidate viral vaccines, the development of serological assays for influenza virus, and methods of vaccine evaluation.
Jason is involved in various WHO projects, working with global partners to ensure effective seasonal and pandemic global influenza vaccine campaigns.
Dr Javier Martin completed his PhD studies at the Universidad Autonoma, Madrid, Spain, in 1992, successfully developing a novel technique to generate genetically modified influenza viruses.
He then spent 5 years as a post-doctoral scientist at the National Institute for Medical Research, Mill Hill, London, where he used this technique to study the effect of site-directed mutations on the properties of mutant influenza viruses.
Javier moved to NIBSC in 1998 where he is currently a Principal Scientist responsible for regulatory and research aspects related to poliovirus, with a special interest on the surveillance for poliomyelitis and the quality control and standardization of poliovaccines.
He is currently the director of the WHO Global Specialised Polio Laboratory at NIBSC, overseeing the surveillance for poliovirus in the UK, Ireland and Cyprus and supporting all 140 WHO polio network laboratories globally.
Job Titles:
- Head of CJD Research and Resource Centre
- Principal Scientist in the Division of Virology
Dr Jillian Cooper has been a principal scientist in the division of Virology since 2001 when the CJD resource centre was established at NIBSC. She has overseen the generation of reference reagents for use in the evaluation of tests intended for the diagnosis of vCJD. Together with other national and international TSE groups, who oversee the work of the resource centre, a protocol has been established to determine fair and appropriate access to extremely rare samples from clinical cases of vCJD. The resource centre works closely with test developers to ensure sample requirements are met.
Jillian has a special interest in protein misfolding disorders and has over 15 years' research in this area. During a postdoctoral fellowship at Johns Hopkins School of Medicine she established a cell culture model of disease related aggregation for Huntington's disease and investigated possible mechanisms of cell death associated with disease.
Jillian is a molecular biologist by training and obtained her PhD in the Department of Virology at the University of Glasgow working on Herpes Simplex Virus (HSV).
Job Titles:
- Senior Scientist, Haemostasis Section
John joined NIBSC in 2004 as a scientist involved in control testing of coagulation factors. Since then John has gained a PhD from King's College London where he investigated the non-anticoagulant function of heparin and has progressed to become a senior scientist in the Haemostasis Section at NIBSC. His main areas of responsibility encompass the control testing and standardisation of coagulation inhibitors (antithrombin, protein C and protein S) and the standardisation of both unfractionated and low molecular weight heparin. He is involved in standardisation of assay methods with a special interest in global coagulation assays such as thrombin generation test and thromboelastography, producing a number of reference reagents to support these assays. His research focuses on novel activities of heparin and related polysaccharides, collaborating with Professor Clive Page at King's College London
Job Titles:
- Principal Scentist and Leader of Mass Spectrometry and Proteomics
With her first degree in Chinese Medicine, Jun was a registered hospital pharmacist in Shanghai. It was during her postgraduate training in the School of Pharmacy in Sydney, that she developed a strong interest in analytical chemistry. During her PhD in Australia, she became one of the pioneers involved in the research and technology developments underpinning the ‘proteome' concept. After that, she worked in two world leading proteomic groups to further her proteomics expertise and academic understanding. Before moving to NIBSC in 2003, she was a proactive scientist in a large company developing state-of-the-art proteomic platforms where she gained valuable experience in an industrial environment.
Leading the Mass Spectrometry & Proteomic group, Jun has established a large number of internal and external collaborations through the use of her extensive knowledge and experience in proteomics, in particular, in its application to the characterisation and development of vaccines and biotherapeutics. She is highly motivated to bring success to NIBSC and her collaborators.
Kevin Markey has an interest in:
bacterial virulence
pathogenesis and toxins
control testing of vaccines and biological standardisation
For his PhD he studied the virulence mechanisms of the Burkholderia cepacia complex of lung pathogens, receiving his doctorate from the Institute of Technology, Tallaght, Dublin, Ireland in 2003. He continued investigating this family of bacteria as a post-doctoral scientist at the University of Liverpool.
Kevin joined NIBSC in 2006, initially working on tuberculosis vaccines before joining the pertussis group in 2011, where he is responsible for the batch release of acellular pertussis combination vaccines and WHO pre-qualification testing of whole cell pertussis vaccines. He is also responsible for the anthrax study area.
He also has responsibility for pertussis standards, including developing new standards. His current research interests include:
Bordetella pertussis genomics and proteomics
assay development
standardisation of pertussis serology.
Kevin also has an interest in developing assays to replace current regulatory tests.
He has published scientific papers, assisted in the establishment of WHO International Standards, and contributed to WHO workshops on quality control testing of vaccines. He is always interested in developing new collaborations.
Job Titles:
- Head, Biological Imaging Group
Job Titles:
- Senior Scientist - Immunohaematology
Job Titles:
- Member of the NIBSC Management Team
- Interim Director
Job Titles:
- Head of Sequencing Technologies
Job Titles:
- Section Leader, Cytokines & Growth Factors
Job Titles:
- Group Leader
- Principal Scientist
Job Titles:
- Member of the NIBSC Management Team
- Head Infectious Disease Diagnostics Division
- Head of Infectious Disease Diagnostics
Job Titles:
- Senior Scientist, Physico - Chemical Analysis Group
Job Titles:
- Member of the NIBSC Management Team
- Head of Virology
- Head of Virology Division
Job Titles:
- Member of the NIBSC Management Team
- Principal Scientist
- Acting Head of Analytical and Biological Sciences
Job Titles:
- Principal Scientist and Section Head, Standardisation Science Technology
Job Titles:
- Member of the NIBSC Management Team
- Acting Head of Bacteriology
- Head of Toxins Group, Interim Head of Bacteriology Division
Job Titles:
- Principal Scientist, Pneumococcal Group
Job Titles:
- Senior Scientist, Molecular Immunology Section
Job Titles:
- Section Leader, Cellular Immunology
Job Titles:
- Principal Scientist, Haemostasis Section
Job Titles:
- Section Leader, Molecular Immunology
Job Titles:
- Senior Scientist and Commercial Project Manager, Haemostasis Section
Job Titles:
- Leader of Gene Therapy Section
Job Titles:
- Member of the NIBSC Management Team
- Head of NIBSC Corporate Affairs
Job Titles:
- Member of the NIBSC Management Team
- Agency Head of Infrastructure and Operations